D
David Hemingway
Researcher at Leicester Royal Infirmary
Publications - 39
Citations - 2935
David Hemingway is an academic researcher from Leicester Royal Infirmary. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 18, co-authored 39 publications receiving 2682 citations. Previous affiliations of David Hemingway include University Hospitals of Leicester NHS Trust & University of Leicester.
Papers
More filters
Journal ArticleDOI
Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance
Ricky A. Sharma,Stephanie A. Euden,Sharon L. Platton,Darren N. Cooke,Aisha Shafayat,Heather R. Hewitt,Timothy H. Marczylo,Bruno Morgan,David Hemingway,Simon M. Plummer,Munir Pirmohamed,Andreas J. Gescher,William P. Steward +12 more
TL;DR: A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract in patients with advanced colorectal cancer refractory to standard chemotherapies.
Journal ArticleDOI
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients
Ketan R. Patel,Victoria A. Brown,Donald J. L. Jones,Robert G. Britton,David Hemingway,Andrew S. Miller,Kevin West,Tristan D. Booth,Marjorie Perloff,James A. Crowell,Dean E. Brenner,William P. Steward,Andreas J. Gescher,Karen Brown +13 more
TL;DR: Resveratrol merits further clinical evaluation as a potential colorectal cancer chemopreventive agent after it was found to be well tolerated and to produce levels in the human gastrointestinal tract of an order of magnitude sufficient to elicit anticarcinogenic effects.
Journal ArticleDOI
Ubiquitous Elevation of Matrix Metalloproteinase-2 Expression in the Vasculature of Patients With Abdominal Aneurysms
TL;DR: Patients with AAA have elevated MMP-2 levels in the vasculature remote from the aorta, which support both the systemic nature of aneurysmal disease and a primary role of M MP-2 in aneurYSm formation.
Journal ArticleDOI
Pilot Study of Oral Silibinin, a Putative Chemopreventive Agent, in Colorectal Cancer Patients: Silibinin Levels in Plasma, Colorectum, and Liver and Their Pharmacodynamic Consequences
Carmen S L Hoh,David J. Boocock,Tim Marczylo,Rajinder Singh,David P. Berry,Ashley R. Dennison,David Hemingway,Andrew S. Miller,Kevin West,Stephanie A. Euden,Giuseppe Garcea,Peter B. Farmer,William P. Steward,Andreas J. Gescher +13 more
TL;DR: The high silibinin levels achieved in the human colorectal mucosa after consumption of safe silib inin doses support its further exploration as a potential human coloresctal cancer chemopreventive agent.
Journal ArticleDOI
Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice
Hong Cai,Edwina N. Scott,Abeer O. Kholghi,Catherine Andreadi,Alessandro Rufini,Ankur Karmokar,Robert G. Britton,Emma Horner-Glister,Peter Greaves,Dhafer Jawad,Mark I. James,Lynne M. Howells,Ted J. Ognibene,Michael A. Malfatti,Christopher E. Goldring,Neil R. Kitteringham,Joanne Walsh,Maria Viskaduraki,Kevin West,Andrew S. Miller,David Hemingway,William P. Steward,Andreas J. Gescher,Karen Brown +23 more
TL;DR: It is shown that a low rather than a high dose of resveratrol prevents tumor growth in mice and alters metabolic pathways in human tissues and suggests that it's time for a revision in development strategies for preventative dietary agents.